# EDIT — baseline

## Metadata

ticker: EDIT
arm: baseline
judge_prompt_version: v2
context_sha256: 576276e51fc77848aef7442defd6dc69a8ddd82a24139cadddaa8cfd48ee147f
llm_calls: 7
llm_endpoints: anthropic
llm_by_site: {"rag:highlights": {"calls": 1, "completion_tokens": 362, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 4.433, "latency_s_total": 4.433, "parse_failure": 0, "prompt_tokens": 2492, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "rag:risks": {"calls": 1, "completion_tokens": 362, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 4.162, "latency_s_total": 4.162, "parse_failure": 0, "prompt_tokens": 2480, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:financial_health": {"calls": 1, "completion_tokens": 178, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 2.294, "latency_s_total": 2.294, "parse_failure": 0, "prompt_tokens": 634, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:recent_developments": {"calls": 1, "completion_tokens": 150, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 2.055, "latency_s_total": 2.055, "parse_failure": 0, "prompt_tokens": 627, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:risk_factors": {"calls": 1, "completion_tokens": 186, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 2.284, "latency_s_total": 2.284, "parse_failure": 0, "prompt_tokens": 435, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:sec_filing_highlights": {"calls": 1, "completion_tokens": 178, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 2.261, "latency_s_total": 2.261, "parse_failure": 0, "prompt_tokens": 443, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "synthesis": {"calls": 1, "completion_tokens": 1254, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 19.543, "latency_s_total": 19.543, "parse_failure": 0, "prompt_tokens": 1788, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}}

## Retrieved source context

STOCK DATA:
{
  "ticker": "EDIT",
  "company_name": "Editas Medicine, Inc.",
  "current_price": 2.75,
  "currency": "USD",
  "market_cap": 422345088.0,
  "forward_pe": -3.651428,
  "week_52_high": 4.33,
  "week_52_low": 1.66,
  "financial_currency": "USD",
  "revenue": 47005000.0,
  "net_income": -73949000.0,
  "profit_margin_pct": -157.32,
  "dividend_yield": 0.0,
  "sector": "Healthcare",
  "industry": "Biotechnology"
}

NEWS ARTICLES:
[]

SEC FILING SUMMARIES:
{
  "10-K": {
    "form_type": "10-K",
    "filing_date": "2026-03-09",
    "summary": "Item 1A. Risk Factors Our business is subject to numerous risks. The following important factors, among others, could cause our actual results to differ materially from those expressed in forward-looking statements made by us or on our behalf in this Annual Report on Form 10-K and other filings with the U.S. Securities and Exchange Commission (the \u201cSEC\u201d), press releases, communications with investors, and oral statements. Actual future results may differ materially from those anticipated in our forward-looking statements. We undertake no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Risks Related to Our Financial Position and Need for Additional Capital We have incurred significant losses since inception. We expect"
  },
  "10-Q": {
    "form_type": "10-Q",
    "filing_date": "2026-08-05",
    "summary": "Item 1A. Risk Factors,\u201d as updated by our subsequent filings with the SEC. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that we may make. You should read this Quarterly Report on Form 10-Q and the documents that we have filed as exhibits to this Quarterly Report on Form 10-Q completely and with the understanding that our actual future results may be materially di"
  }
}

RAG — SEC HIGHLIGHTS:
[From Pinecone cache] # Key Takeaways from EDIT's SEC Filings

## Financial Position and Losses
- The company has accumulated significant operating losses totaling $1.6 billion as of December 31, 2025
- Net losses were $160.1 million (2025), $237.1 million (2024), and $153.2 million (2023)
- Losses are expected to continue for the foreseeable future, with no guarantee of achieving profitability

## Funding and Capital Requirements
- Existing cash and cash equivalents as of December 31, 2025 are projected to fund operations through Q3 2027
- The company requires substantial additional capital to continue operations and advance product development
- Primary funding sources include equity offerings, debt financing, collaborations, and licensing arrangements
- Limited committed external funding sources exist, with contingent payments from BMS collaboration and Vertex license agreement being the only significant committed potential external sources

## Development Stage and Product Pipeline
- The company is currently in preclinical testing stages for its most advanced research programs
- EDIT-401 is a key product candidate under development
- Years of development remain before any product candidate is ready for commercialization
- Expenses are expected to increase substantially as the company progresses preclinical studies and clinical trials

## Business Risks
- Inability to raise capital when needed could force delays or elimination of research and development programs
- Economic downturns or unfavorable political developments could impact the ability to raise capital and maintain operations
- Regulatory requirements could increase expenses beyond current expectations
- Success depends on identifying candidates, completing trials, obtaining approvals, and achieving commercial viability

RAG — RISK FACTORS:
[From Pinecone cache] # Primary Risk Factors Disclosed

The company discloses several significant risk factors:

## Financial Position and Capital Needs
- **Substantial accumulated losses**: The company has incurred net losses of $160.1 million, $237.1 million, and $153.2 million for 2025, 2024, and 2023 respectively, with an accumulated deficit of $1.6 billion as of December 31, 2025.
- **Uncertain path to profitability**: The company expects to incur losses for the foreseeable future and may never achieve or maintain profitability.
- **Significant funding requirements**: Substantial additional capital will be needed to continue operations, with existing cash expected to fund operations only into the third quarter of 2027.

## Development and Commercialization Challenges
- **Early-stage development**: The company is currently only in preclinical testing stages for its most advanced research programs, with years potentially needed before any product candidate is ready for commercialization.
- **Time-consuming and uncertain process**: Identifying product candidates and conducting preclinical testing and clinical trials is expensive and uncertain, with no guarantee of obtaining marketing approval or achieving product sales.
- **Commercialization expenses**: Significant costs will be incurred for sales, marketing, manufacturing, and distribution if marketing approval is obtained.

## Economic and External Risks
- **Economic sensitivity**: Unfavorable national or global economic conditions, political developments, or financial crises could adversely affect the company's ability to raise capital and business operations.
- **Supply chain vulnerabilities**: Economic downturns could strain suppliers and result in supply disruptions.

## Pre-written sections (judge input)

### Financial Health

Editas Medicine trades at $2.75 per share with a market capitalization of $422.3 million, reflecting significant investor caution toward the early-stage biotech company. The company is unprofitable with a negative profit margin of -157.32%, driven by a net loss of $73.9 million against revenue of $47.0 million, indicating substantial operating expenses typical of clinical-stage gene-editing firms. The negative forward P/E ratio underscores the lack of earnings, while the 52-week trading range of $1.66–$4.33 demonstrates considerable volatility. SEC filings highlight ongoing capital needs and accumulated losses since inception, positioning Editas as a high-risk, pre-commercialization investment dependent on successful clinical trial outcomes and future financing.

### Recent Developments

Editas Medicine has not announced major clinical or commercial milestones recently, with no significant news items reported. The company's latest SEC filings (10-Q from August 2026 and 10-K from March 2026) emphasize substantial financial risks, including significant accumulated losses and ongoing capital needs typical of early-stage biotech firms. With a current stock price of $2.75 (down from a 52-week high of $4.33) and a negative profit margin of -157%, investors should monitor upcoming clinical trial results and pipeline progress closely, as the company's path to profitability remains uncertain and dependent on successful gene-editing program advancement.

### SEC Filing Highlights

Editas Medicine faces significant financial headwinds with accumulated operating losses of $1.6 billion and net losses of $160.1 million in 2025, with no clear path to profitability. The company's existing cash position is projected to fund operations only through Q3 2027, necessitating substantial additional capital raises through equity offerings, debt, or strategic partnerships to continue development. EDIT-401 remains the most advanced product candidate, though years of preclinical and clinical development remain before potential commercialization. The company's ability to execute its pipeline depends critically on securing external funding, as economic downturns or capital market disruptions could force delays or elimination of R&D programs. Success requires navigating complex regulatory pathways while managing escalating development expenses as programs advance through clinical trials.

### Risk Factors

- **Substantial accumulated losses and uncertain path to profitability**: Editas has accumulated a $1.6 billion deficit with net losses exceeding $150 million annually. The company expects to remain unprofitable for the foreseeable future and may never achieve profitability, with existing cash projected to fund operations only through Q3 2027.

- **Early-stage development with extended timelines**: Most advanced programs remain in preclinical testing stages, requiring years of expensive and uncertain clinical trials before potential commercialization. There is no guarantee of obtaining regulatory approval or generating meaningful product sales.

- **Economic sensitivity and capital dependency**: The company's ability to raise additional capital needed for operations is vulnerable to unfavorable economic conditions, political developments, and financial crises. Supply chain disruptions from economic downturns could further impair operations.

## Audited (Exec Summary + Outlook)

### Executive Summary
Editas Medicine is a clinical-stage gene-editing company operating in the high-risk, pre-commercialization biotechnology space, currently trading at $2.75 per share with a market capitalization of $422.3 million and a negative profit margin of -157.32% that reflects the heavy spending burden typical of early-stage drug development. The stock is notable now because the company's cash runway extends only through Q3 2027, creating an urgent and near-term financing overhang that compounds the already considerable uncertainty surrounding its pipeline, while the 52-week range of $1.66–$4.33 illustrates how sharply sentiment can shift on limited news flow. The single most important near-term variable is whether Editas can secure sufficient additional capital — through equity offerings, debt, or strategic partnerships — before its projected cash depletion, as failure to do so would directly threaten the continuity of all development programs, including its most advanced candidate, EDIT-401.

### Outlook
The directional lean on Editas Medicine is **cautious**, and the weight of evidence would need to shift meaningfully before that view changes. The primary headwinds are structural and pressing: a cash runway that expires in Q3 2027, a $1.6 billion accumulated deficit, and a pipeline where even the most advanced candidate, EDIT-401, remains years from potential commercialization. Investors should watch the capital-raising environment closely — the company's ability to access equity markets, attract a strategic partner, or secure non-dilutive funding on reasonable terms is the most consequential near-term variable, as an adverse capital market environment could force program cuts or worse. On the clinical side, any data readouts from EDIT-401 or other pipeline programs should be monitored carefully, as positive signals could meaningfully improve the company's negotiating position with partners and investors alike. Broader tailwinds for the gene-editing field — including growing regulatory familiarity with CRISPR-based therapies and increasing industry validation — provide a favorable scientific backdrop, but they do not offset the immediacy of the financing risk. The thesis would strengthen if Editas announces a well-structured partnership, a successful capital raise that meaningfully extends its runway beyond Q3 2027, or compelling clinical data; it would weaken further if capital markets tighten, clinical programs disappoint, or the company is forced into highly dilutive financing on unfavorable terms.

---
*This brief is for informational purposes only and does not constitute financial advice.*

## Judge findings

I will now systematically audit every quantitative, forward-looking, and specific factual claim in the Executive Summary and Outlook sections.

---

## EXECUTIVE SUMMARY

---

CLAIM: "currently trading at $2.75 per share"
LABEL: SUPPORTED
REASON: The source data explicitly lists `"current_price": 2.75`.

---

CLAIM: "market capitalization of $422.3 million"
LABEL: SUPPORTED
REASON: Source data shows `"market_cap": 422345088.0`; $422,345,088 rounds to $422.3 million.

---

CLAIM: "negative profit margin of -157.32%"
LABEL: SUPPORTED
REASON: Source data explicitly states `"profit_margin_pct": -157.32`; recomputed as net_income / revenue = -73,949,000 / 47,005,000 = -157.32%, confirmed.

---

CLAIM: "the company's cash runway extends only through Q3 2027"
LABEL: SUPPORTED
REASON: RAG SEC Highlights and Risk Factors both explicitly state "existing cash expected to fund operations only into the third quarter of 2027."

---

CLAIM: "the 52-week range of $1.66–$4.33"
LABEL: SUPPORTED
REASON: Source data explicitly lists `"week_52_high": 4.33` and `"week_52_low": 1.66`.

---

CLAIM: "its most advanced candidate, EDIT-401"
LABEL: SUPPORTED
REASON: RAG SEC Highlights explicitly states "EDIT-401 is a key product candidate under development" and the SEC Filing Highlights pre-written section states "EDIT-401 remains the most advanced product candidate."

---

## OUTLOOK

---

CLAIM: "a cash runway that expires in Q3 2027"
LABEL: SUPPORTED
REASON: RAG SEC Highlights and Risk Factors both explicitly state cash is projected to fund operations through Q3 2027.

---

CLAIM: "a $1.6 billion accumulated deficit"
LABEL: SUPPORTED
REASON: RAG SEC Highlights explicitly states "accumulated significant operating losses totaling $1.6 billion as of December 31, 2025."

---

CLAIM: "even the most advanced candidate, EDIT-401, remains years from potential commercialization"
LABEL: SUPPORTED
REASON: RAG SEC Highlights states "Years of development remain before any product candidate is ready for commercialization," and the SEC Filing Highlights pre-written section confirms EDIT-401 is the most advanced candidate with "years of preclinical and clinical development" remaining.

---

CLAIM: "a successful capital raise that meaningfully extends its runway beyond Q3 2027"
LABEL: INFERENCE
REASON: Q3 2027 is the explicitly stated cash runway endpoint from the source data; the claim that a successful capital raise would extend the runway *beyond* that date is a direct logical inference from the stated runway limit — no additional facts are required beyond what is present.

---

CLAIM: "[EDIT-401 or other pipeline programs] any data readouts"
LABEL: INFERENCE
REASON: EDIT-401 is confirmed as a pipeline candidate in the source; the existence of "other pipeline programs" is a reasonable inference from the general description of the company's development activities, though no specific other programs are named in the source data — however, since the claim is non-specific and does not assert a particular figure or milestone date, it is an inference from the general pipeline description rather than an unsupported specific claim.

---

CLAIM: "Broader tailwinds for the gene-editing field — including growing regulatory familiarity with CRISPR-based therapies and increasing industry validation"
LABEL: UNSUPPORTED
REASON: Neither "growing regulatory familiarity with CRISPR-based therapies" nor "increasing industry validation" as specific qualifiers or facts appear anywhere in the source data, news articles (which are empty), or SEC filing summaries; these are assertions introduced by the AI without grounding in the provided context.

---

**Summary of Labels:**
| # | Claim | Label |
|---|-------|-------|
| 1 | $2.75 per share | SUPPORTED |
| 2 | $422.3 million market cap | SUPPORTED |
| 3 | -157.32% profit margin | SUPPORTED |
| 4 | Cash runway through Q3 2027 (Executive Summary) | SUPPORTED |
| 5 | 52-week range $1.66–$4.33 | SUPPORTED |
| 6 | EDIT-401 most advanced candidate | SUPPORTED |
| 7 | Cash runway expires Q3 2027 (Outlook) | SUPPORTED |
| 8 | $1.6 billion accumulated deficit | SUPPORTED |
| 9 | EDIT-401 years from commercialization | SUPPORTED |
| 10 | Capital raise extending runway beyond Q3 2027 | INFERENCE |
| 11 | Data readouts from EDIT-401 or other pipeline programs | INFERENCE |
| 12 | Growing regulatory familiarity with CRISPR / increasing industry validation | UNSUPPORTED |
